

Robert Greene Sterne Edward J. Kessler Jorge A. Goldstein David K S Conwell Robert W. Esmond Tracy-Gene G. Durkin Michele A. Cimbala Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee Steven R. Ludwig John M. Covert Linda E. Alcorn Robert C. Millonig Donald J. Featherstone Timothy J. Shea, Jr Michael V. Messinger Judith U. Kim

Patrick E. Garrett Jeffrey T. Helvey Heidi L. Kraus Fldora L. Fllison Thomas C. Fiala Albert L. Ferro Donald R. Banowit Peter A. Jackman Jeffrey S. Weaver Kendrick P. Patterson Vincent L. Capuano Brian J. Del Buono Virgil Lee Beaston Theodore A. Wood Elizabeth J. Haanes Joseph S. Ostroff Frank R. Cottingham Rae Lynn P. Guest George S. Bardmesser Daniel A. Klein Jason D. Eisenberg Michael D. Specht Andrea J. Kamage Tracy L. Muller Jon E. Wright LuAnne M. DeSantis Ann E. Summerfield Aric W. Ledford Helene C. Carlson Timothy A. Doyle Gaby L. Longsworth Lori A. Gordon Nicole D. Dretar Laura A. Vogel Michael J. Mancuso Bryan S. Wade

Aaron L. Schwartz Michael G. Penn' Shannon A. Carroll\* Wesley W. Jones\* Matthew E. Kelley\* Nicole R. Kramer Michelle K. Holoubeks Marsha A. Rose

Registered Patent Agents Karen R. Markowicz Nancy J. Leith Katrina Yujian Pei Quach Bryan L. Skelton Robert A. Schwartzman Teresa A. Colella Victoria S. Rutherford

Julie A. Heider Mita Mukherjee Scott M. Woodhouse Christopher J. Walsh Liliana Di Nola-Baron Peter A. Socarras Jeffrey Mills

Of Counsel
Kenneth C. Bass III Marvin C. Guthrie

Admitted only in Maryland Admitted only in Virginia Practice Limited to Federal Agencies

WRITER'S DIRECT NUMBER: (202) 772-8773 **INTERNET ADDRESS:** MDOWD@SKGF.COM

Art Unit 1653

August 4, 2005

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Utility Patent Application

Application No. 09/767,080; Filed: January 22, 2001

Deoxo-Proline-Containing Tamandarin and Didemnin Analogs, Dehydro-Proline-Containing Tamandarin and Didemnin Analogs, and Methods of Making and Using Them

Inventors:

JOULLIÉ et al.

Our Ref:

1694.0640001

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. PTO-2038 Credit Card Payment Form to cover: \$180.00 Second Supplemental Information Disclosure Statement fee;
- 2. Fourth Supplemental Information Disclosure Statement Filing Under 37 C.F.R. § 1.97(d) and (e)(1) (3 pp.);
- 3. Forms PTO-SB/08a and SB/08b (2 pages) listing the cited documents;
- Copies of six of the nine cited documents; and
- 5. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

-08/05/2005/JBALYNAN\_00000085/09767080

01/ EE=1806

180.00 OP

Commissioner for Patents August 4, 2005 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Matthew J. Dowd Agent for Applicants Registration No. 47,534

JMC/MJD/bls Enclosures

428751\_1.DOC

Sterne, Kessler, Goldstein & Fox PLL.c.: 1100 New York Avenue, NW: Washington, DC 20005: 202.371.2600 f 202.371.2540: www.skgf.com



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

JOULLIÉ et al.

Appl. No.: 09/767,080

Filed: January 22, 2001

For: Deoxo-Proline-Containing

Tamandarin and Didemnin Analogs,

**Dehydro-Proline-Containing** 

Tamandarin and Didemnin Analogs, and Methods of Making and Using Them

Confirmation No.: 5576

Art Unit: 1653

Examiner: Abdel A. Mohamed

Atty. Docket: 1694.0640001

## Fourth Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(d) and (e)(1)

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO/SB/08A and Form PTO/SB/08B are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. Copies of documents **FP1-FP4, NPL1**, and **NPL2** are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents, documents **US1-US3**, cited on the attached PTO/SB/08A are not submitted.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following discussion of the relevance of the non-English language document **FP1** cited on Form PTO/SB/08A:

Document FP1, ES2 102 322 A1, is in the Spanish language. An English language abstract of document FP1 is attached as document NPL1 on Form

PTO/SB/08B. Additionally, document **NPL2** is a published research article which is believed to be an English equivalent of part or all of the disclosure of document **FP1**.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached Form PTO/SB/08A and Form PTO/SB/08B based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed after the mailing of the Notice of Allowance. In accordance with the requirements of 37 C.F.R. § 1.97(d) and (e)(1), I hereby state that each item of information contained in this Information Disclosure Statement (with the exception of documents NPL1 and NPL2) was first cited in a communication from a foreign patent office in a counterpart foreign application not

more than three months prior to the filing of this Information Disclosure Statement. Attached is our PTO-2038 Credit Card Payment Form in the amount of \$ 180.00 in payment of the fee under 37 C.F.R. § 1.17(p). Additionally, the fee set for in 37 C.F.R. § 1.17(p) is enclosed herewith.

It is respectfully requested that the Examiner initial and return copies of the enclosed Form PTO/SB/08A and Form PTO/SB/08B, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Matthew J. Bowd Agent for Applicants Registration No. 47,534

Date: August 4, 2005

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

428826\_1.DOC

AUG 0 4 2005

Substitute for

Sheet

Equivalent of Form PTO/SB/08A (08-03)
Approved for use through 07/31/2006.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

perwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known		
Application Number	09/767,080	
Filing Date	January 22, 2001	
First Named Inventor	Madeleine M. Joullié	
Art Unit	1653	
Examiner Name	Mohamed, Abdel A.	
Attorney Docket Number	1694.0640001	

	U.S. PATENT DOCUMENTS					
	Examiner Cite Initials No. 1		Document Number  Number-Kind Code <sup>2 (If Known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	
1	2	USI	4,782,135	11/01/1988	Rinehart, Jr.	
		US2	4,493,796	01/15/1985	Rinehart, Jr.	
	<u> </u>	US3	5,504,189	04/02/1996	Emling et al.	
) (	2005				·	
	MARKET		<u> </u>			
D	Min					
			<del>                                     </del>			
			·		<del> </del>	
			<del> </del>			

			FOREIGN PATENT DOCUMENTS		
Examiner Initials*	Cite No.	Foreign Patent Document  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	
	FP1	ES2 102 322 A1	07/16/1997	Pharma Mar	
	FP2	WO 98/17302 A1	04/30/1998	The Board of Trustees of the University of Illinois	
	FP3	WO 98/17302 A1 (Corrected Version)	04/30/1998	The Board of Trustees of the University of Illinois	
	FP4	WO 98/17275 A1	04/30/1998	The Board of Trustees of the University of Illinois	

428824 1.DOC

Examiner	Date	
Signature	Con	sidered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
POLIDMIL CLIPPL PLANTA I			ENION A F	Application Number	09/767,080
FOURTH SUPPLEMENTAL		Filing Date	January 22, 2001		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				First Named Inventor	Madeleine M. Joullié
				Art Unit	1653
			s necessary)	Examiner Name	Mohamed, Abdel A.
Sheet	1	of	1	Attorney Docket Number	1694.0640001

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>	
	NPL1	STNEasy/CAplus English language abstract of document FP1, ES2102322A1, Accession No. 1998:169709		
	NPL2	Jou, G., et al., "Total Synthesis of Dehydrodidemnin B. Use of Uronium and Phosphonium Salt Coupling Reagents in Peptide Synthesis in Solution," <i>J. Org. Chem.</i> 62:354-366, American Chemical Society (1997).		
	!	·		

428829 1.DOC

Examiner	Date
Signature	Considered
Signature	Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.